There is no reliable treatment for ineffective esophageal motility (IEM), a disorder caused by failed smooth-muscle contraction that is common in patients with gastroesophageal reflux disease.

Dazostinag sodium is under clinical development by Takeda Pharmaceutical and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer.

TAK-861 is under clinical development by Takeda Pharmaceutical and currently in Phase I for Unspecified Neurologic Disorders.

Management often involves dietary modifications, medications to enhance gastric motility ... effective treatment and support for those affected by this challenging digestive disorder.